JID Journal Supplement: Tuberculosis Drug Development

Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis

Volume 211 suppl 3 June 15, 2015

Click here for access to supplement


  • Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen Development J Infect Dis. (2015) 211 (suppl 3): S81-S82 doi:10.1093/infdis/jiv072
More News
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...